EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).

被引：1
|
作者：
Mise, Yoshihiro
Hasegawa, Kiyoshi
Oba, Masaru
Yamaguchi, Kensei
Uetake, Hiroyuki
Yoshino, Takayuki
Morita, Satoshi
Takahashi, Keiichi
Unno, Michiaki
Shimada, Yasuhiro
Muro, Kei
Yoshida, Kazuhiro
Mori, Masaki
Baba, Hideo
Shimada, Mitsuo
Saiura, Akio
Matsumura, Masaru
Ishigure, Kiyoshi
Sugihara, Kenichi
Kokudo, Norihiro
机构：
[1] Japanese Fdn Canc Res, Tokyo, Japan
[2] Univ Tokyo, Tokyo, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[5] Tokyo Med & Dent Univ, Dept Specialized Surg, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[8] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Tokyo, Japan
[9] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[10] Kochi Hlth Sci Ctr, Kochi, Japan
[11] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[12] Gifu Univ, Grad Sch Med, Dept Surg Oncol, Gifu, Japan
[13] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan
[14] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan
[15] Tokushima Univ, Tokushima, Japan
[16] Konan Kosei Hosp, Konan, Japan
[17] Tokyo Med & Dent Univ, Tokyo, Japan
[18] Natl Ctr Global Hlth & Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
652
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, (vol 34, pg 1723, 2016)
    van Hazel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 4059 - 4059
  • [32] TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
    Borelli, Beatrice
    Moretto, Roberto
    Lonardi, Sara
    Bonetti, Andrea
    Antoniotti, Carlotta
    Pietrantonio, Filippo
    Masi, Gianluca
    Burgio, Valentina
    Marmorino, Federica
    Salvatore, Lisa
    Rossini, Daniele
    Zaniboni, Alberto
    Zucchelli, Gemma
    Martignetti, Angelo
    Di Battista, Monica
    Pella, Nicoletta
    Passardi, Alessandro
    Boccaccino, Alessandra
    Leone, Francesco
    Colombo, Camilla
    Granetto, Cristina
    Vannini, Francesca
    Marsico, Valentina Angela
    Martinelli, Erika
    Antonuzzo, Lorenzo
    Vitello, Stefano
    Delliponti, Laura
    Boni, Luca
    Cremolini, Chiara
    Falcone, Alfredo
    ESMO OPEN, 2018, 3 (04)
  • [33] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial
    Heinrich, Kathrin
    Heinemann, Volker
    Westphalen, Benedikt
    Oecal, Osman
    Van Hazel, Guy A.
    Gibbs, Peter
    Seidensticker, Max
    Ricke, Jens
    Seidensticker, Ricarda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 ns first-line treatment for metastatic colorectal cancer (mCRC); Interim results.
    Hecht, J. R.
    Yoshio, T.
    Mitchell, E. P.
    Dees, M. S., III
    Countouriotis, A. M.
    Maneval, E. C.
    Kretzschmar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] SUNITINIB PLUS 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MFOLFOX6) VS. BEVACIZUMAB PLUS MFOLFOX6 IN FRST-LINE METASTATIC COLORECTAL CANCER (MCRC) - INTERIM RESULTS OF A RANDOMIZED, PHASE IIB STUDY
    Hecht, J.
    Yoshino, T.
    Mitchell, E.
    Dees, M.
    Kroening, H.
    Patel, R.
    Welslau, M.
    Dakhil, S.
    Yamazaki, K.
    Maneval, Chow E.
    Kretzschmar, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [36] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [37] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hoehler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Ting, Saskia
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kosbade, Karina
    Worm, Karl
    Schmid, Kurt Werner
    Herold, Thomas
    Schuler, Martin H.
    Trarbach, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/III rectal cancer receiving pre-operative chemoradiation
    Benson, Al Bowen
    Zhao, Fengmin
    Meropol, Neal J.
    Catalano, Paul J.
    Chakravarthy, Bapsi
    Flynn, Patrick J.
    Catalano, Robert B.
    Giantonio, Bruce J.
    Mitchell, Edith P.
    Haller, Daniel G.
    Leichman, Cynthia G.
    Petrelli, Nicholas J.
    Sinicrope, Frank A.
    Tepper, Joel E.
    Brierley, James D.
    Sigurdson, Elin R.
    Whittington, Richard M.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers
    Satoshi Nagayama
    Suguru Hasegawa
    Koya Hida
    Kenji Kawada
    Etsuro Hatano
    Kojiro Nakamura
    Satoru Seo
    Kojiro Taura
    Kentaro Yasuchika
    Takashi Matsuo
    Masazumi Zaima
    Akiyoshi Kanazawa
    Hiroaki Terajima
    Masaharu Tada
    Yukihito Adachi
    Ryuta Nishitai
    Dai Manaka
    Tsunehiro Yoshimura
    Koji Doi
    Takahiro Horimatsu
    Akira Mitsuyoshi
    Kenichi Yoshimura
    Miyuki Niimi
    Shigemi Matsumoto
    Yoshiharu Sakai
    Shinji Uemoto
    International Journal of Clinical Oncology, 2017, 22 : 316 - 323
  • [40] Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers
    Nagayama, Satoshi
    Hasegawa, Suguru
    Hida, Koya
    Kawada, Kenji
    Hatano, Etsuro
    Nakamura, Kojiro
    Seo, Satoru
    Taura, Kojiro
    Yasuchika, Kentaro
    Matsuo, Takashi
    Zaima, Masazumi
    Kanazawa, Akiyoshi
    Terajima, Hiroaki
    Tada, Masaharu
    Adachi, Yukihito
    Nishitai, Ryuta
    Manaka, Dai
    Yoshimura, Tsunehiro
    Doi, Koji
    Horimatsu, Takahiro
    Mitsuyoshi, Akira
    Yoshimura, Kenichi
    Niimi, Miyuki
    Matsumoto, Shigemi
    Sakai, Yoshiharu
    Uemoto, Shinji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (02) : 316 - 323
12345